Emami Reports Solid Q4 Performance, Marks 50 Years with Special Dividend

Homegrown FMCG firm Emami Ltd has announced a robust performance for the fourth quarter of the fiscal year 2024-25, reporting an increase in consolidated profit after tax. The company's board also approved a special interim dividend for shareholders, coinciding with its 50th anniversary.

Financial Highlights for Q4 FY25

For the January-March quarter of FY25, Emami posted a consolidated profit after tax (PAT) of ₹162.17 crore. This represents a 10.5% increase compared to the PAT of ₹146.75 crore recorded in the same period last year. The growth in profit was supported by healthy volume growth in the company's core business.

Revenue from operations for the quarter stood at ₹963.05 crore, up from ₹891.24 crore in the corresponding year-ago period. This reflects an 8.1% year-on-year increase in revenue. Emami's total income, which includes other income, also saw an uptick, rising by 9.12% to ₹984.21 crore. Meanwhile, total expenses for the quarter reached ₹743.61 crore, marking a 9.3% increase year-on-year.

Full Year FY25 Performance

Looking at the full fiscal year, Emami's PAT for FY25 increased by 10.85% to ₹802.74 crore, compared to ₹724.14 crore in the previous fiscal year. Total income for FY25 rose by 6.9% to ₹3,877.30 crore.

Special Dividend Declaration

In a move to celebrate the company's 50-year milestone, Emami's board approved the payment of a special (interim) dividend. The dividend is set at ₹2 per equity share of face value ₹1 each for the financial year 2024-25. This special dividend is equivalent to 200% on the 43,65,00,000 equity shares of the company. The record date for determining the members entitled to receive this interim dividend has been fixed as Thursday, May 22, 2025.

Market Performance

The Q4 results were announced after market hours, with the stock closing with a modest gain of 0.72% at ₹634.50.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here